Three-dimensional Assessment of Intraventricular Dyssynchrony Using Fast Dobutamine Gated SPECT

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02510677

Acronym

FAST DOGS

Enrollment

Registered

2015-07-29

Start date

2013-06-30

Completion date

2017-01-31

Last updated

2017-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

The prognosis of patients with heart failure has improved due to recent breakthrough in medical treatment and cardiac resynchronization devices. However, there is no paraclinical parameter to assess response to cardiac resynchronization therapy (CRT). This is a major issue since about a third of implanted patients will not be improved by CRT. CZT SPECT allows to perform myocardial perfusion imaging in less than 4 minutes and is able to study myocardial perfusion, viability, left ventricular function, but also ventricular asynchrony. Using low-dose dobutamine gated SPECT and CZT camera, we aimed to assess left ventricular dyssynchrony in viable segments in patients with heart failure eligible for CRT.

Interventions

OTHERmyocardial perfusion scintigraphy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient with heart failure on optimal medical therapy and targeted for cardiac resynchronization therapy according to current recommendations; * Age over 18 years * Clinically stable (without hospitalization for heart failure in the last month) * Sinus rhythm * Social security insurance * Signed consent form

Exclusion criteria

* Recent history (less than 21 days) of acute coronary syndrome or unstable angina; * Recent history (less than 1 month) of acute heart failure; * Right bundle branch block; * Irregular heart rate; * Double-chamber cardiac pacemaker * Patients previously implanted with a single-chamber cardioverter-defibrillator must have at least 99 percent of unstimulated QRS. * Countraindication to dobutamine therapy; * Valvular heart disease, congenital heart disease, hypertrophic cardiomyopathy; * Significant Ventricular arrhythmias; * Hypertension (upper than 160/100 mmHg); * Pregnant, breastfeeding or guardianship

Design outcomes

Primary

Measure	Time frame	Description
measures of dyssynchrony parameters	baseline	The primary endpoint is reproducible quantitative measures of dyssynchrony parameters between two successive acquisitions basal (entropy, bandwidth, standard deviation phase histogram).

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026